Panel: Comparing Modality Selection Decisions to Match Biology & Indication Requirements

• Examining how biology, delivery constraints & safety risk shaped final modality choices 
• Weighing durability, tissue access, reversibility & tolerability across competing strategies 
• Identifying modality decision principles that remain consistent across CNS & peripheral programs 

Speakers:

Stefan McDonough

Adjunct Professor of Brain Science

Brown University

Alejandro Amador

Vice President of R&D and Operations

Navega Therapeutics

Fabricio Simao

Senior Principal Scientist

Quiver Bioscience

Edward Humphries

Director of Discovery Biology

Maxion Therapeutics

Alexei Pushechnikov

Vice President MedChem

Mair Therapeutics